Taysha Gene Therapies Stock Performance
| TSHA Stock | USD 1.72 0.02 1.15% |
The entity has a beta of 0.66, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, Taysha Gene's returns are expected to increase less than the market. However, during the bear market, the loss of holding Taysha Gene is expected to be smaller as well. At this point, Taysha Gene Therapies has a negative expected return of -0.18%. Please make sure to validate Taysha Gene's potential upside, day median price, and the relationship between the treynor ratio and accumulation distribution , to decide if Taysha Gene Therapies performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Taysha Gene Therapies has generated negative risk-adjusted returns adding no value to investors with long positions. Despite latest weak performance, the Stock's technical indicators remain strong and the current disturbance on Wall Street may also be a sign of long term gains for the company investors. ...more
| Begin Period Cash Flow | 146.5 M |
Taysha |
Taysha Gene Relative Risk vs. Return Landscape
If you would invest 201.00 in Taysha Gene Therapies on December 14, 2024 and sell it today you would lose (29.00) from holding Taysha Gene Therapies or give up 14.43% of portfolio value over 90 days. Taysha Gene Therapies is currently does not generate positive expected returns and assumes 3.9674% risk (volatility on return distribution) over the 90 days horizon. In different words, 35% of stocks are less volatile than Taysha, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Taysha Gene Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Taysha Gene's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Taysha Gene Therapies, and traders can use it to determine the average amount a Taysha Gene's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0464
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | TSHA |
Estimated Market Risk
| 3.97 actual daily | 35 65% of assets are more volatile |
Expected Return
| -0.18 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.05 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Taysha Gene is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Taysha Gene by adding Taysha Gene to a well-diversified portfolio.
Taysha Gene Fundamentals Growth
Taysha Stock prices reflect investors' perceptions of the future prospects and financial health of Taysha Gene, and Taysha Gene fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Taysha Stock performance.
| Return On Equity | -1.22 | ||||
| Return On Asset | -0.33 | ||||
| Operating Margin | (9.86) % | ||||
| Current Valuation | 276.75 M | ||||
| Shares Outstanding | 205 M | ||||
| Price To Book | 4.93 X | ||||
| Price To Sales | 42.81 X | ||||
| Revenue | 8.33 M | ||||
| EBITDA | (87.95 M) | ||||
| Cash And Equivalents | 66.24 M | ||||
| Cash Per Share | 1.61 X | ||||
| Total Debt | 17.36 M | ||||
| Debt To Equity | 1.93 % | ||||
| Book Value Per Share | 0.35 X | ||||
| Cash Flow From Operations | (81.22 M) | ||||
| Earnings Per Share | (0.36) X | ||||
| Total Asset | 160.36 M | ||||
| Retained Earnings | (602.3 M) | ||||
About Taysha Gene Performance
By analyzing Taysha Gene's fundamental ratios, stakeholders can gain valuable insights into Taysha Gene's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Taysha Gene has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Taysha Gene has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. The company was incorporated in 2019 and is based in Dallas, Texas. Taysha Gene operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 178 people.Things to note about Taysha Gene Therapies performance evaluation
Checking the ongoing alerts about Taysha Gene for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Taysha Gene Therapies help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Taysha Gene generated a negative expected return over the last 90 days | |
| Taysha Gene may become a speculative penny stock | |
| Taysha Gene has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 8.33 M. Net Loss for the year was (89.3 M) with profit before overhead, payroll, taxes, and interest of 8.33 M. | |
| Taysha Gene Therapies currently holds about 66.24 M in cash with (81.22 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.61. | |
| Taysha Gene has a poor financial position based on the latest SEC disclosures | |
| Over 83.0% of the company shares are owned by institutional investors |
- Analyzing Taysha Gene's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Taysha Gene's stock is overvalued or undervalued compared to its peers.
- Examining Taysha Gene's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Taysha Gene's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Taysha Gene's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Taysha Gene's stock. These opinions can provide insight into Taysha Gene's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Taysha Stock analysis
When running Taysha Gene's price analysis, check to measure Taysha Gene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Taysha Gene is operating at the current time. Most of Taysha Gene's value examination focuses on studying past and present price action to predict the probability of Taysha Gene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Taysha Gene's price. Additionally, you may evaluate how the addition of Taysha Gene to your portfolios can decrease your overall portfolio volatility.
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Bonds Directory Find actively traded corporate debentures issued by US companies |